{
  "abstract": "Despite intensive lowering of low-density lipoprotein cholesterol (LDL-C), many patients continue to experience atherosclerotic cardiovascular disease (ASCVD) events, with cholesterol-enriched remnant lipoproteins contributing to this residual risk. This review examines the evidence linking remnant lipoproteins to residual ASCVD risk and evaluates which treatment-induced changes in remnant exposure are likely to reduce it. Lipoprotein lipase (LPL), transported to the capillary lumen by GPIHBP1, converts triglyceride-rich lipoproteins into smaller remnants, the concentration of which is then determined by further remodeling and hepatic uptake. Once retained in the arterial wall, these remnants deliver cholesterol to macrophages and promote inflammation. In cohort studies, remnant cholesterol (RC) predicts cardiovascular events even among patients receiving lipid-lowering therapy, while Mendelian randomization and coding-variant analyses implicate LPL and its regulators in coronary artery disease. Trials evaluating triglyceride-lowering therapies, however, have yielded inconsistent results. In PROMINENT, pemafibrate lowered RC but elevated apolipoprotein B (apoB) and failed to reduce events. Agents targeting apolipoprotein C-III or angiopoietin-like protein 3 substantially lower triglycerides; their effects on RC, LDL-C, and apoB differ by agent and population; in the ESSENCE imaging study, olezarsen reduced both RC and apoB without significantly altering non-calcified plaque volume at 1 year. Building upon recent syntheses, we propose that these findings are best interpreted by separating four related dimensions of exposure: the cholesterol carried per remnant particle, the number of remnant particles, total apoB-containing particle exposure, and the rate of particle clearance. We apply this remnant-cholesterol-load framework to classify trial responses and to identify the measurements that future outcome trials should include. The framework is interpretive, and its dimensions are mathematically and kinetically related rather than independent; it has not been tested prospectively. At present, RC serves as a useful complement in assessing residual dyslipidemia; whether its reduction decreases events will be established only by outcome trials incorporating serial lipid and particle measurements.",
  "abstract_shown": true,
  "affiliations": [
    "Key Laboratory of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases of Ministry of Education, First Affiliated Hospital of Gannan Medical University, Gannan Medical University",
    "Heart Medical Center, The First Affiliated Hospital of Gannan Medical University",
    "First Clinical Medical College, Gannan Medical University",
    "The First Affiliated Hospital of Gannan Medical University"
  ],
  "article_type": null,
  "arxiv": null,
  "author_total": 4,
  "authors": [
    {
      "affs": [
        0,
        1
      ],
      "name": "Yuting Huang"
    },
    {
      "affs": [
        2
      ],
      "name": "Luyao Lin"
    },
    {
      "affs": [
        2
      ],
      "name": "Feng Liu"
    },
    {
      "affs": [
        3
      ],
      "name": "Xiaoping Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/dtwhzmpd5m753.bib",
  "cited_by": 0,
  "doi": "10.3389/fcvm.2026.1967973",
  "fulltext_url": "https://www.frontiersin.org/articles/10.3389/fcvm.2026.1967973/full",
  "id": "dtwhzmpd5m753",
  "issns": [
    "2297-055X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fcvm.2026.1967973/full",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "lcc",
      "RC666-701"
    ]
  ],
  "openalex": null,
  "pdf_url": null,
  "pmcid": null,
  "pmid": null,
  "published": "2026-11-16",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/dtwhzmpd5m753.ris",
  "sources": [
    {
      "first_seen": "2026-11-16T12:25:40Z",
      "native_id": "10.3389/fcvm.2026.1967973",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fcvm.2026.1967973/full"
    },
    {
      "first_seen": "2026-11-16T15:21:14Z",
      "native_id": "02c4e3b4d693414d8aa10617de4aa38b",
      "source": "doaj",
      "url": "https://doi.org/10.3389/fcvm.2026.1967973"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "lcc:RC666-701",
      "subfield": "cardiovascular"
    }
  ],
  "title": "Remnant lipoproteins and remnant cholesterol in residual atherosclerotic cardiovascular risk",
  "title_text": "Remnant lipoproteins and remnant cholesterol in residual atherosclerotic cardiovascular risk",
  "type": "peer-reviewed",
  "updated_at": "2026-11-16T15:21:14Z",
  "url": "https://research.draconitic.com/paper/dtwhzmpd5m753",
  "venue": "Frontiers in Cardiovascular Medicine",
  "versions": []
}